MOG and myeloid sarcoma: No differences were found in the anti-MOG autoantibody content in total EVs among the healthy controls (0.99 ± 0.16 ng/mL), the white matter lesion control group (1.07 ± 1.01 ng/mL), and the patients with MS (0.86 ± 0.47 ng/mL) (Figure 3B).